Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryHighmark Blueshield Neny botulinum toxin Prior Aut…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Botulinum toxin prior authorization — chronic migraine, hyperhidrosis, and other uses

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization information and clinical questions required for medical benefit administration of botulinum toxin for chronic migraine, hyperhidrosis, and other uses for Highmark BlueShield regions. Affects ordering providers, administering facilities, and specialty pharmacies submitting requests.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyBotulinum toxin prior authorization — chronic migraine, hyperhidrosis, and other uses
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form including ICD-10 diagnosis, drug J-code, dose/units, frequency, number of visits, and indication-specific supporting documentation (eg headache diary for chronic migraine).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Named indication sections
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Listed HCPCS/J-codes
    2Response types

    Coverage Criteria for Botulinum Toxin

    Chronic Migraine

    Covered when ALL of the following are met

    Chronic migraine coverage criteria: 1) Diagnosis of chronic migraine established using the International Classification of Headache Disorders, Third Edition (ICHD-III); 2) Persistent three-month history of recurrent debilitating headache documented by the member via headache diary or calendar; 3) Headache frequency and duration responses provided (days per month and hours per episode); 4) Request prescribed by or in consultation with a neurologist or headache specialist; 5) Administration by a healthcare provider trained in botulinum toxin (Botox) administration; 6) Prior trials and failures of adequate prophylactic therapy from at least two different therapy classes (e.g., antiseizure, beta blocker, tricyclic antidepressant) with adequate dose/duration; 7) For continuation of therapy, objective clinical response since starting botulinum toxin defined as ≥50% reduction in migraine frequency or ≥50% reduction in migraine hours from baseline.>=50% reduction for continuation response

    Form requests fields to document each element

    Hyperhidrosis

    Covered when ALL of the following are met

    Hyperhidrosis coverage criteria: 1) Severe focal hyperhidrosis present and the treatment region specified (axillary, palmar, plantar, craniofacial, or other); 2) History of failed or intolerant topical therapy (e.g., 20% aluminum chloride or extra-strength antiperspirants) and/or systemic pharmacotherapy for excessive sweating (e.g., anticholinergics, beta-blockers, benzodiazepines); 3) Documentation of recurrent skin maceration with bacterial or fungal infections or refractory atopic dermatitis despite medical treatments when applicable; 4) For continuation of therapy, documented objective measurable improvement in response to treatment (e.g., improvement in HDSS).objective measurable improvement (eg HDSS)

    Form asks to describe improvement

    Other Indications

    Covered when ALL of the following are met

    Other indications coverage criteria: 1) List of all therapies tried and failed, not tolerated, or contraindicated for the diagnosis provided on the form; 2) For continuation of therapy, documentation of a documented positive clinical response to treatment; 3) Attach supporting documentation as requested on the form (e.g., clinical notes, outcome measures).

    Form provides fields to capture prior therapies and response

    Requests for botulinum toxin for chronic migraine are excluded when headaches are attributable to reversible causes such as medication rebound or identifiable lifestyle issues rather than true chronic migraine. The prior authorization form explicitly asks whether headaches are caused by medication rebound or lifestyle factors; an affirmative response indicates the condition may not meet chronic migraine criteria and should be addressed before considering coverage for chronic migraine treatment.

    A request may be considered incomplete or may be denied if the submission lacks documentation of required prior therapy trials, specialist involvement when requested, or the member’s treatment history. Specifically, the form requires documentation that the diagnosis meets ICHD-III criteria, confirmation of a persistent three-month headache diary/calendar history, and evidence of trials and failures of at least two prophylactic therapy classes. In addition, if the form indicates that a neurologist or headache specialist prescribed or was consulted, supporting documentation should be included; absence of a trained administrator or missing treatment details (drug, dose, duration, and response) can also render the request incomplete.

    Relevant Codes

    Listed Botulinum Toxin HCPCS/J-codesHCPCS
    J0585BOTOX
    J0586DYSPORT
    J0587MYBLOC
    J0588XEOMIN

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for botulinum toxin injections. Submit a completed prior authorization request form that includes the requested drug (name and HCPCS/J‑code), dose/units, frequency, number of visits, diagnosis (ICD‑10 code(s)), requested start date, and indication‑specific fields. Requests must be submitted prior to initiation of treatment per payer requirements.

    • Include drug name and HCPCS/J‑code (e.g., BOTOX J0585; DYSPORT J0586; MYOBLOC J0587; XEOMIN J0588)
    • Dose / number of units and frequency
    • Number of visits requested
    • ICD‑10 diagnosis code(s) and requested start date
    • Provider and member identifiers (member name, DOB, member ID/UMI), ordering/attending provider name, NPI, office contact, phone, fax, servicing facility name and NPI
    Denial Risk

    Chronic Migraine Documentation — Denial Risk

    Key Definitions

    inv-13: Definition — Chronic migraine
    DefinitionRecurrent debilitating headache established using the International Classification of Headache Disorders, Third Edition (ICHD-III).
    Documentation requirementPersistent three-month history documented by the member via a headache diary or calendar.
    Specialist involvementRequest must be prescribed by or in consultation with a neurologist or headache specialist.
    AdministrationMust be administered by a healthcare provider trained in botulinum toxin administration.
    Prior therapy trialsMember must have tried and failed adequate trials of prophylactic therapy from at least two different therapy classes (e.g., antiseizure, beta blocker, tricyclic antidepressant).
    Continuation thresholdFor continuation requests, objective response required: ≥50% reduction in headache frequency or hours from baseline since starting botulinum toxin.

    Background

    Chronic migraine is characterized by frequent, disabling headaches and is evaluated using the International Classification of Headache Disorders, Third Edition (ICHD-III). The prior authorization form requests objective documentation of a persistent three-month history of recurrent debilitating headache via a headache diary or calendar to establish frequency and duration. Botulinum toxin injections are administered in the outpatient setting by a healthcare provider trained in botulinum toxin administration; the form also captures whether the request is prescribed by or in consultation with a neurologist or headache specialist as part of medical necessity evaluation.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyBotulinum toxin prior authorization — chronic migraine, hyperhidrosis, and other uses
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form including ICD-10 diagnosis, drug J-code, dose/units, frequency, number of visits, and indication-specific supporting documentation (eg headache diary for chronic migraine).
    SourceLink
    On This Page
    Coverage Criteria for Botulinum ToxinRelevant CodesProvider Actions, Documentation & Prior AuthorizationKey DefinitionsBackground

    For chronic migraine, the prior authorization form must document a persistent 3‑month history of recurring debilitating headaches and include objective documentation such as a headache diary or calendar. Failure to provide the 3‑month headache history, headache diary/calendar, or documentation of prior prophylactic therapy trials (including doses and duration) may result in denial.

    • Number of headache days per month, average duration in hours, and duration of the chronic pattern
    • Confirm diagnosis per ICHD‑III (yes/no) and whether managed by or in consultation with a neurologist/headache specialist
    • Documentation of a 3‑month headache history via diary/calendar is required
    • List of prior prophylactic therapies tried from at least two different classes (e.g., antiseizure, beta‑blocker, tricyclic antidepressant), with reason for failure, intolerance, or contraindication and whether prescribed at adequate dose/duration (example benchmark: ~6 weeks)
    Documentation Required

    Required Form Fields & Attachments

    The completed prior authorization form must include member and provider identifiers, ICD‑10 code(s), requested start date, the specific drug and HCPCS/J‑code, dose/units, frequency, number of visits requested, and any applicable attachments (evidence of prior therapies, headache diary, objective response measures). Missing required fields or missing attachments increases risk of delayed processing or denial.

    • Member name, DOB, member ID (UMI)
    • Ordering/attending provider name, NPI, address, office contact, phone, fax
    • Servicing facility/vendor name and NPI
    • ICD‑10 diagnosis code(s) and requested start date of service
    • Drug name and HCPCS/J‑code, dose/units, frequency, number of visits requested
    • Indication‑specific fields and attachments (e.g., headache diary for chronic migraine; documentation of severe focal hyperhidrosis and prior topical/systemic therapy trials for hyperhidrosis)
    • Attach documentation of prior therapy trials, reasons for failure/intolerance/contraindication, and any objective response measures (e.g., HDSS for hyperhidrosis)
    inv-14: Definition — Severe hyperhidrosis
    DefinitionFocal excessive sweating (axillary, palmar, plantar, craniofacial, or other) described as severe hyperhidrosis.
    Prior topical therapyTopical products such as 20% aluminum chloride or other extra‑strength antiperspirants must have been ineffective or caused a severe rash.
    Systemic therapyMember must have been unresponsive to or unable to tolerate systemic pharmacotherapy for excessive sweating (e.g., anticholinergics, beta‑blockers, benzodiazepines).
    Clinical consequencesDocumentation of recurrent skin maceration with bacterial or fungal infections or persistent atopic dermatitis despite treatments when applicable.
    Treatment regionsRegion(s) treated should be specified (axillary, palmar, plantar, craniofacial, or other).
    Continuation responseFor continuation, documented objective measurable improvement is required (e.g., improvement in Hyperhidrosis Disease Severity Scale (HDSS)).